ArticleRevista panamericana de salud publica = Pan American journal of public health2017
[Public production as a key factor for access to antivenoms in the Region of the Americas].
Article in Revista panamericana de salud publica = Pan American journal of public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Strengthening public health programmes and the antivenom ecosystem: strategic policy priorities to combat envenomation by animal bites and stings in Latin America and the Caribbean.Journal of global health · 2026Article
- Overcoming Limited Access to Virus Infection Rapid Testing: Development of a Lateral Flow Test for SARS-CoV-2 with Locally Available Resources.Biosensors · 2024Article
- Variability in antivenom neutralization of Mexican viperid snake venoms.PLoS neglected tropical diseases · 2024Article
- Standard Quality Characteristics and Efficacy of a New Third-Generation Antivenom Developed in Colombia CoveringToxins · 2024Article
- Epidemiology of Snake Bites Linked with the Antivenoms Production in Colombia 2008-2020: Produced Vials Do Not Meet the Needs.Drug, healthcare and patient safety · 2022Article
- Biotechnological potential of Phospholipase D forToxicon: X · 2020Review
- Economic Evaluations of Interventions for Snakebites: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2020Review
- [Situation of public laboratories manufacturing antivenoms in Latin AmericaA situação dos laboratórios públicos produtores de soros antivenenos na América Latina].Revista panamericana de salud publica = Pan American journal of public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injuries caused by venomous animals affect vast areas of Latin America, Southern Asia, Southeast Asia, sub-Saharan Africa, and Oceania, and pose a serious problem for global public health. Based on an analysis of the current panorama of global production of ophidian and arachnid antivenoms, it is concluded that they are semi-orphaned products. This is a favorable scenario in which to strengthen public laboratory production. Governments should make a political decision in this regard in the interest of equity in population health. In the Region of the Americas, these actions could be part of a program led by the Pan American Health Organization to ensure the availability of these biologicals in strategically located health centers. Twelve public facilities producing antivenoms have been identified in the Region, including Brazil and Mexico, which are the biggest public producers. These laboratories should be managed like industrial operations that produce tangible goods without ignoring strategic planning. National regulatory authorities should help the public laboratories that produce them by providing necessary technical assistance and consultancy without any loss of impartiality or rigor in the evaluation of their quality management systems. New superior production technologies using hyperimmune mammalian plasma are in the experimental phase; no information on its production has been found in the literature.
Indexed as
Identifiers
28902267PMC6645312W2738068656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.